Why the study?
Conflicting results have been reported regarding the optimum duration of DAPT in ACS patients, and recent randomized trials in this setting warrant a reconsideration of practice and guidelines.
Does a shorter duration of DAPT reduce major bleeding complications without increasing thrombotic risk compared to traditional 12-month DAPT in ACS patients?
Population
ACS patients, especially those treated with PCI and modern DES
Comparison
Shorter DAPT strategy vs traditional 12-month DAPT
Design
Comprehensive review
Key result
A shorter duration of dual antiplatelet therapy is noninferior to traditional 12-month DAPT in acute coronary syndrome patients, reducing the risk of major bleeding complications.
Authors
Loading...
May support shorter DAPT to reduce bleeding in ACS; leaves open confirmatory RCTs before practice change.
Does a shorter duration of DAPT reduce major bleeding complications without increasing thrombotic risk compared to traditional 12-month DAPT in ACS patients?
A shorter duration of DAPT may be noninferior to traditional 12-month DAPT in ACS patients, reducing major bleeding complications and prompting a reconsideration of current guidelines.
Verdoia et al. (2020) conducted a review in Acute Coronary Syndrome (ACS). Shorter duration dual antiplatelet therapy (DAPT) vs. Traditional 12-month DAPT was evaluated. A shorter duration of dual antiplatelet therapy is noninferior to traditional 12-month DAPT in acute coronary syndrome patients, reducing the risk of major bleeding complications.